TRINETRA › Sectors › Healthcare
Wockhardt Limited (WOCKPHARMA) — share price, P/E and fundamentals
Wockhardt Limited (NSE: WOCKPHARMA) closed at ₹1,901.10 on 30 Oct 2026, +41.6% over one year, against a 52-week range of ₹1,086.70 – ₹2,422.30.
In the quarter ended 30 Jun 2026 (consolidated, filed 10 Aug 2026) it reported revenue of ₹929 cr and net profit of ₹106 cr, a 11.4% net margin; revenue grew 25.9% year on year.
On four consecutive filed quarters its trailing P/E is 75.3; since 10 Feb 2026 its own P/E has ranged from 70.9 to 1,098.7 (median 144.3), and today's reading is higher than 9% of those 175 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 8.6%, ROCE 9.6%, debt-to-equity 0.43, Piotroski F-score 8 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 36% of 63 sector peers; PBT margin higher than 24% of 63 sector peers; ROE higher than 18% of 63 sector peers.
Key figures
| Last close | ₹1,901.10 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -16.9% / +35.3% / +41.6% |
| 52-week low – high | ₹1,086.70 – ₹2,422.30 |
| Market capitalisation | ₹30,798 cr |
| Trailing P/E | 75.3 |
| Price / book | 6.23 |
| EV / EBITDA | 36.1 |
| Earnings yield | 1.3% |
| TTM EPS | ₹25.25 |
| TTM net profit | ₹409 cr |
| Quarter revenue | ₹929 cr |
| Quarter net profit | ₹106 cr |
| Net margin | 11.4% |
| Revenue growth (YoY) | +25.9% |
| Return on equity | 8.6% |
| ROCE | 9.6% |
| Debt / equity | 0.43 |
| Current ratio | 1.61 |
| Free cash flow | ₹254 cr |
| Piotroski F-score | 8 / 9 |
| Average daily turnover (50 days) | ₹149.3 cr |
Against Healthcare peers
| Metric | WOCKPHARMA | Peer median | Percentile |
|---|---|---|---|
| Net margin | 11.41 | 12.89 | 37 |
| PBT margin | 12.49 | 17.68 | 24 |
| ROE | 8.58 | 13.87 | 18 |
| ROCE | 9.61 | 17.26 | 18 |
| Debt / equity | 0.43 | 0.11 | 84 |
| Cash conversion | 1.96 | 1.25 | 82 |
| Trailing P/E | 75.30 | 43.07 | 78 |
| P/B | 6.23 | 5.88 | 55 |
Questions
What is the P/E ratio of Wockhardt Limited?
Wockhardt Limited's trailing P/E is 75.3, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 10 Feb 2026 its P/E has ranged 70.9–1,098.7.
What were Wockhardt Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Wockhardt Limited reported revenue of ₹929 cr and net profit of ₹106 cr (consolidated), filed with the exchange on 10 Aug 2026.
What is Wockhardt Limited's ROE?
Return on equity is 8.6% based on the balance sheet dated 31 Mar 2026.
Does Wockhardt Limited have debt?
Debt-to-equity is 0.43 on the balance sheet dated 31 Mar 2026.
What is WOCKPHARMA's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, WOCKPHARMA traded between ₹1,086.70 and ₹2,422.30.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.